title: Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma.
authors.forename: Monica
authors.initials: M
authors.lastname: Civallero
authors.forename: Maria
authors.initials: M
authors.lastname: Cosenza
authors.forename: Alessia
authors.initials: A
authors.lastname: Bari
authors.forename: Stefano
authors.initials: S
authors.lastname: Sacchi
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage; D007211:Indoles / Q000008:administration & dosage*; D000077269:Lenalidomide; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D058990:Molecular Targeted Therapy / Q000379:methods; D000069283:Rituximab; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D007211:Indoles; D000069283:Rituximab; D013792:Thalidomide; D000077269:Lenalidomide; C504878:enzastaurin